Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 227 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 9, 2026 | clinicaltrials |
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 18, 2026 |
| clinicaltrials |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT04879979 | GIST and Memory and Attention Adaptation Training(GIST-MAAT) | terminated | N/A | 2 | University of PittsburghOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01034670 | Advanced Gastrointestinal Endoscopic Imaging | terminated | N/A | 3 | Stanford UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03291054 | Epacadostat and Pembrolizumab in Patients With GIST | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05160168 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 1 / Phase 2 | 32 | Theseus PharmaceuticalsINDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04276415 | DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 1 | 34 | Daiichi SankyoINDUSTRY | 2 | Feb 15, 2024 | clinicaltrials |
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02232620 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | terminated | Phase 2 | 2 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00812240 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | terminated | Phase 3 | 335 | AB ScienceINDUSTRY | 3 | Feb 1, 2023 | clinicaltrials |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02185937 | Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy(ABILITY) | terminated | Phase 1 | 5 | Radboud University Medical CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 2 | 25 | Kristen GanjooOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01089595 | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 2 | 5 | Fox Chase Cancer CenterOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT00585221 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02488746 | Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST) | terminated | — | 5 | Kliniken Ludwigsburg-Bietigheim gGmbHOTHER | 1 | Dec 9, 2016 | clinicaltrials |
| NCT00767234 | Permission to Collect Blood Over Time for Research | terminated | — | 104 | Stanford UniversityOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT00009906 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | terminated | Phase 3 | 748 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT01031628 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | terminated | Phase 3 | 5 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00091078 | Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery | terminated | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00782834 | Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)(07060) | terminated | Phase 2 | 13 | Fox Chase Cancer CenterOTHER | 1 | Apr 22, 2013 | clinicaltrials |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | terminated | N/A | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | terminated | Phase 3 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00956072 | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | terminated | Phase 3 | 12 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00573404 | Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 16, 2011 | clinicaltrials |
| NCT00372567 | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | terminated | Phase 3 | 69 | PfizerINDUSTRY | 7 | Mar 17, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jul 9, 2026source: clinicaltrials